Traders Sell Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Wednesday. $86.30 million flowed into the stock on the tick-up and $212.66 million flowed out of the stock on the tick-down, for a money net flow of $126.36 million out of the stock. Of all equities tracked, Pfizer had the 8th highest net out-flow for the day. Pfizer traded up $0.25 for the day and closed at $35.19

Several brokerages have recently commented on PFE. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, November 16th. JPMorgan Chase & Co. set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Nord/LB restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $39.45.

The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $209,760.00, a PE ratio of 10.00, a price-to-earnings-growth ratio of 1.96 and a beta of 0.94.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the business earned $0.47 earnings per share. analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

Pfizer declared that its Board of Directors has authorized a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

In other news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Pfizer by 2.8% in the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after purchasing an additional 12,183,218 shares in the last quarter. Mackenzie Financial Corp raised its stake in Pfizer by 29,164.7% in the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock valued at $415,878,000 after purchasing an additional 11,442,753 shares in the last quarter. Janus Henderson Group PLC raised its stake in Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after purchasing an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. raised its stake in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Pfizer by 81.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock valued at $691,583,000 after purchasing an additional 8,563,358 shares in the last quarter. Institutional investors own 70.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/traders-sell-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply